The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Quantitation of circulating methylated RASSF1A in prognostication and monitoring of treatment response in unresectable hepatocellular carcinoma (HCC).
S. L. Chan
No relevant relationships to disclose
A. K. Chan
No relevant relationships to disclose
E. P. Hui
No relevant relationships to disclose
S. Yu
No relevant relationships to disclose
L. Leung
No relevant relationships to disclose
H. H. F. Loong
No relevant relationships to disclose
B. Ma
No relevant relationships to disclose
T. Mok
No relevant relationships to disclose
A. T. C. Chan
No relevant relationships to disclose
W. Yeo
No relevant relationships to disclose